Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026
Key Highlights
- ➤Trevi will report Q3 2026 financial results on November 9, 2026
- ➤Management will provide a corporate update during the November 9 conference call
- ➤Haduvio targets chronic cough in IPF, non-IPF ILD, and refractory chronic cough
- ➤Haduvio showed statistically significant cough-frequency reductions in clinical trials
NEW HAVEN, Conn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio(™) (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Monday, November 9, 2026, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended September 30, 2026.
Conference Call and Webcast To register for the live conference call and webcast, please visit the ‘Investors & News’ section of the Company’s website or access directly at ir.trevitherapeutics.com/news-events/events. Please note for phone participants: Once registered, you will receive an email with unique call-in details. An archived replay of the webcast will also be available for 30 days on the Company's website following the event.
Get started
Create a free account to read the full story.